A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Christopher J Sweeney, MBBS
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Brasschaat, Belgium
- Research Site
Ghent, Belgium
- Research Site
Bordeaux, France
- Research Site
Villejuif, France
- Research Site
Goyang-si, South Korea
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
Barcelona, Spain
- Research Site
Barcelona, Spain
- Research Site
Hospitalet deLlobregat, Spain
- Research Site
Madrid, Spain
- Research Site
Sacramento, California, United States
- Research Site
Tampa, Florida, United States
- Research Site
Atlanta, Georgia, United States
- Research Site
St Louis, Missouri, United States
- Research Site
Winston-Salem, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Aug 2020
- Primary completion
- 1 Nov 2021
- Completion
- 8 Aug 2022
- Last update posted
- 9 Aug 2023
- Registered enrollment
- 30
- Registry id
- NCT04495179
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.